Research programme: Alzheimer's disease therapies - NicOx

Drug Profile

Research programme: Alzheimer's disease therapies - NicOx

Alternative Names: NCX 2057; NCX 2213

Latest Information Update: 16 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Jul 2004 Preclinical trials in Alzheimer's disease in Italy (unspecified route)
  • 23 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to Pharmacodynamics section
  • 17 Jul 2000 Preclinical development for Alzheimer's disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top